Wealth Enhancement Trust Services’s BioCryst Pharmaceuticals BCRX Stock Holding History

Wealth Enhancement Trust Services’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$980	Buy	+98	New	+$886	﹤0.01%	1134

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Wealth Enhancement Trust Services's BCRX Position: Q2 2026 in Review

Wealth Enhancement Trust Services opened a new position in BioCryst Pharmaceuticals (BCRX) in Q2 2026: 98 shares worth $980. The stake represents ﹤0.01% of the portfolio and ranks #1134 among its holdings.

194 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

Wealth Enhancement Trust Services held 98 shares of BioCryst Pharmaceuticals worth $980 as of Q2 2026.
BioCryst Pharmaceuticals was a new Wealth Enhancement Trust Services position in Q2 2026.
BioCryst Pharmaceuticals made up ﹤0.01% of Wealth Enhancement Trust Services's portfolio in Q2 2026, its #1134 holding.
194 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Wealth Enhancement Trust Services's 13F filing for Q2 2026, filed 15 Jul 2026.